Coya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a research note issued to investors on Thursday,Benzinga reports. They currently have a $15.00 price target on the stock.

Other equities analysts have also recently issued research reports about the stock. Chardan Capital reiterated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Thursday, November 7th. HC Wainwright reissued a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, November 11th.

Coya Therapeutics Trading Up 1.1 %

Shares of COYA traded up $0.08 during midday trading on Thursday, reaching $6.91. The stock had a trading volume of 50,117 shares, compared to its average volume of 66,442. The company has a market capitalization of $115.43 million, a price-to-earnings ratio of -10.63 and a beta of 0.47. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.69. The company's 50-day moving average is $5.87 and its 200 day moving average is $6.39.

Institutional Investors Weigh In On Coya Therapeutics

Large investors have recently added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. purchased a new stake in shares of Coya Therapeutics during the fourth quarter worth about $401,000. GHP Investment Advisors Inc. bought a new position in Coya Therapeutics during the 3rd quarter valued at approximately $169,000. Renaissance Technologies LLC bought a new position in Coya Therapeutics during the 2nd quarter valued at approximately $101,000. CM Management LLC lifted its holdings in Coya Therapeutics by 11.1% in the 4th quarter. CM Management LLC now owns 160,000 shares of the company's stock worth $917,000 after buying an additional 15,941 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company's stock worth $918,000 after buying an additional 4,485 shares during the last quarter. Institutional investors own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.